Search Results - "Albertsen, B. K."

Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol by Wolthers, B O, Frandsen, T L, Abrahamsson, J, Albertsen, B K, Helt, L R, Heyman, M, Jónsson, Ó G, Kõrgvee, L T, Lund, B, Raja, R A, Rasmussen, K K, Taskinen, M, Tulstrup, M, Vaitkevičienė, G E, Yadav, R, Gupta, R, Schmiegelow, K

“…Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0–17.9 years) diagnosed during…”
Get full text

Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study by Tuckuviene, R., Ranta, S., Albertsen, B. K., Andersson, N. G., Bendtsen, M. D., Frisk, T., Gunnes, M. W., Helgestad, J., Heyman, M. M., Jonsson, O. G., Mäkipernaa, A., Pruunsild, K., Tedgård, U., Trakymiene, S. S., Ruud, E.

“…Essentials Children with acute lymphoblastic leukemia (ALL) are at risk of thromboembolism (TE). This is a prospective evaluation of the incidence, risk…”
Get full text

Immunophenotype-defined sub-populations are common at diagnosis in childhood B-cell precursor acute lymphoblastic leukemia by Øbro, N F, Marquart, H V, Madsen, H O, Ryder, L P, Andersen, M K, Lausen, B, Albertsen, B K, Wehner, P S, Helgestad, J, Schmiegelow, K

Get full text

Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study by Albertsen, Birgitte Klug, Grell, Kathrine, Abrahamsson, Jonas, Lund, Bendik, Vettenranta, Kim, Jónsson, Ólafur G, Frandsen, Thomas L, Wolthers, Benjamin O, Heyman, Mats, Schmiegelow, Kjeld

“…Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is frequently given for months to obtain continuous asparagine…”
Get full text

Acute liver failure in a four-year old girl during maintenance therapy of acute lymphoblastic leukemia by Raja, R. A., Wolthers, B. O., Frandsen, T. L., Albertsen, B. K., Schulz, N., Damholt, M. B., Schmiegelow, K., Jørgensen, M. H.

Get full text

Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration by ALBERTSEN, Birgitte Klug, JAKOBSEN, Preben, SCHRØDER, Henrik, SCHMIEGELOW, Kjeld, CARLSEN, Niels T

“…To describe the pharmacokinetics of Erwinia asparaginase (ASNase) after intravenous (i.v.) and intramuscular (i.m.) administration. A group of 29 children with…”
Get full text

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system by Albertsen, Birgitte Klug, Schrøder, Henrik, Ingerslev, Jørgen, Jakobsen, Preben, Avramis, Vassilios I., Müller, Hans‐Joachim, Carlsen, Niels T., Schmiegelow, Kjeld

“…Asparaginase comes from different biological sources and the various preparations have different pharmacokinetic properties, and their tendency to induce…”
Get full text

Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries by Albertsen, Birgitte Klug, Schrøder, Henrik, Jakobsen, Preben, Müller, Hans‐Joachim, Carlsen, Niels T., Schmiegelow, Kjeld

“…Aims  Evaluation of l‐asparaginase therapy in the NOPHO‐92 ALL‐protocol (treatment protocol of acute lymphoblastic leukaemia of the Nordic Society of…”
Get full text

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia by Lynggaard, Line Stensig, Vaitkeviciene, Goda, Langenskiöld, Cecilia, Lehmann, Anne Kristine, Lähteenmäki, Päivi M., Lepik, Kristi, El Hariry, Iman, Schmiegelow, Kjeld, Albertsen, Birgitte Klug

“…Summary Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase‐related hypersensitivity causes treatment discontinuation,…”
Get full text

Erratum by Egnell, C, Heyman, M, Jonsson, OG, Raja, RA, Niinimaki, R, Albertsen, BK

Get full text

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia by Gottschalk Højfeldt, Sofie, Grell, Kathrine, Abrahamsson, Jonas, Lund, Bendik, Vettenranta, Kim, Jónsson, Ólafur G., Frandsen, Thomas L., Wolthers, Benjamin O., Marquart, Hanne Vibeke, Vaitkeviciene, Goda, Lepik, Kristi, Heyman, Mats, Schmiegelow, Kjeld, Albertsen, Birgitte Klug

“…Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute…”
Get full text

Parental experiences of the informed consent process in randomized clinical trials—A Nordic study by Mogensen, Nina, Kreicbergs, Ulrika, Albertsen, Birgitte Klug, Lähteenmäki, Päivi, Heyman, Mats, Harila, Arja

“…Abstract Background Randomized clinical trials (RCTs) are an essential part of improving acute lymphoblastic leukemia (ALL) treatment. This population‐based…”
Get full text

Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study by Thastrup, Maria, Marquart, Hanne Vibeke, Levinsen, Mette, Grell, Kathrine, Abrahamsson, Jonas, Albertsen, Birgitte Klug, Frandsen, Thomas Leth, Harila-Saari, Arja, Lähteenmäki, Päivi Maria, Niinimäki, Riitta, Pronk, Cornelis Jan, Ulvmoen, Aina, Vaitkevičienė, Goda, Taskinen, Mervi, Schmiegelow, Kjeld

“…Central nervous system (CNS) involvement by cytospin is associated with increased risk of relapse in childhood acute lymphoblastic leukemia. We investigated if…”
Get full text

PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis by Lynggaard, Line Stensig, Rank, Cecilie U, Als-Nielsen, Bodil, Hoejfeldt, Sofie G, Heyman, Mats, Schmiegelow, Kjeld, Albertsen, Birgitte K

“…Asparaginase has played a crucial role in the improvement of survival in children with acute lymphoblastic leukaemia (ALL), which is the commonest cancer among…”
Get more information

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age by Rank, Cecilie U, Wolthers, Benjamin O, Grell, Kathrine, Albertsen, Birgitte K, Frandsen, Thomas L, Overgaard, Ulrik M, Toft, Nina, Nielsen, Ove J, Wehner, Peder S, Harila-Saari, Arja, Heyman, Mats M, Malmros, Johan, Abrahamsson, Jonas, Norén-Nyström, Ulrika, Tomaszewska-Toporska, Beata, Lund, Bendik, Jarvis, Kirsten B, Quist-Paulsen, Petter, Vaitkevičienė, Goda E, Griškevičius, Laimonas, Taskinen, Mervi, Wartiovaara-Kautto, Ulla, Lepik, Kristi, Punab, Mari, Jónsson, Ólafur G, Schmiegelow, Kjeld

“…Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in…”
Get full text

Obesity as a predictor of treatment‐related toxicity in children with acute lymphoblastic leukaemia by Egnell, Christina, Heyman, Mats, Jónsson, Ólafur Gisli, Raja, Raheel A., Niinimäki, Riitta, Albertsen, Birgitte Klug, Schmiegelow, Kjeld, Stabell, Niklas, Vaitkeviciene, Goda, Lepik, Kristi, Harila‐Saari, Arja, Ranta, Susanna

“…Summary Obesity is associated with poor outcomes in childhood acute lymphoblastic leukaemia (ALL). We explored whether severe treatment‐related toxicity and…”
Get full text

Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark by Mogensen, Nina, Saaranen, Ella, Olsson, Erik, Klug Albertsen, Birgitte, Lähteenmäki, Päivi M., Kreicbergs, Ulrika, Heyman, Mats, Harila‐Saari, Arja

“…Summary Acute lymphoblastic leukaemia (ALL) has a high survival rate, but treatment is lengthy with risk of severe side‐effects, which may also impact parents'…”
Get full text

Quality of life in children and adolescents after treatment for acute lymphoblastic leukemia according to the NOPHO ALL2008 protocol by Mogensen, Nina, Kreicbergs, Ulrika, Albertsen, Birgitte Klug, Lähteenmäki, Päivi M., Heyman, Mats, Harila, Arja

“…Background The improved outcome of childhood acute lymphoblastic leukemia (ALL) over the last decades has increased the importance of assessing late effects…”
Get full text

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia by Dam, Merete, Centanni, Maddalena, Friberg, Lena E., Centanni, Daniel, Karlsson, Mats O., Stensig Lynggaard, Line, Johannsdottir, Inga Maria, Wik, Hilde Skuterud, Malmros, Johan, Vaitkeviciene, Goda Elizabeta, Griskevicius, Laimonas, Hallböök, Helene, Jónsson, Ólafur Gísli, Overgaard, Ulrik, Schmiegelow, Kjeld, Hansen, Stefan Nygaard, Heyman, Mats, Albertsen, Birgitte Klug

“…Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation,…”
Get full text

Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population‐based cohort study by Jensen, Karen S., Oskarsson, Trausti, Lähteenmäki, Päivi M., Flaegstad, Trond, Schmiegelow, Kjeld, Vedsted, Peter, Albertsen, Birgitte K., Schrøder, Henrik

“…Summary Relapse constitutes the greatest threat to event‐free survival after completion of treatment for childhood acute lymphoblastic leukaemia (ALL)…”
Get full text